Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-25-241475

Chief Scientific Officer sold 8,500 shares at an average $25.79 ($219,196)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Bredt David Chief Scientific Officer 2025-10-15 Sale 10b5-1 −7,418 $25.73 $190,887 410,724 D
Bredt David Chief Scientific Officer 2025-10-15 Sale 10b5-1 −1,082 $26.16 $28,310 409,642 D
Open-market sales · 8,500 sh · avg $25.79 · $219,196
Loading xslF345X05/ownership.xml…